Project Grant HT94252410227

This $892,929 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting the development of an early detection blood test for universal breast cancer screening. The goal is to improve early diagnosis of breast cancer for women across all social and ethnic backgrounds. The grant recipient, The Governors Of The University Of Calgary (doing business as University Of Calgary), is an international educational...

The National Cancer Institute (NCI) awarded a 5-year, $3,537,456 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Regents of the University of California, San Francisco (UCSF) to conduct research on optimizing subtype-specific breast cancer screening and prevention. The project aims to develop improved risk assessment models that can predict the specific type of breast cancer a woman is likely to develop, in order to tailor screening and prevention...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Johns Hopkins University provides $653,819 to develop an early detection blood-based screening test for pancreatic cancer, called "PancSeek", and to create integrated risk models, called "PancDetect", that leverage clinical, genomic, molecular, and imaging data to guide personalized surveillance plans for high-risk individuals. The overarching goal is...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...

The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Regents of the University of California, San Francisco (UCSF) totaling $679,188. The grant will fund the development of liquid biopsy tests using artificial intelligence-assisted, morphology-based isolation of tumor cells from malignant effusions to evaluate known actionable breast cancer biomarkers and discover new predictive molecular and morphology-based...

The National Cancer Institute (NCI) awarded a $570,634 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of Connecticut to develop a robust, multimodal, and longitudinal artificial intelligence (AI) system to enhance breast cancer screening. The overarching objective is to optimize and personalize breast cancer screening by advancing AI algorithms that can transform clinical decision-making. The key products/services to be delivered...

This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...

This Project Grant award from the National Cancer Institute (NCI), under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), provides $369,354.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the tumor immune microenvironment and response to immunotherapy among different racial and ethnic populations with breast cancer. The key objectives of this research project are: 1) to determine how frequently women of different...

This $989,122 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to evaluate the performance of four commercial mammography-based artificial intelligence (AI) algorithms for breast cancer risk prediction in diverse U.S. screening populations. The project will assess the accuracy and equity of these AI risk models compared to traditional clinical risk factor-based models, using data from the Breast Cancer...

This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports a $644,804 research project titled "Advancing Breast Cancer Risk Assessment for Black Women." The project aims to develop and validate a novel deep learning-based breast cancer risk assessment tool focused on Black women, leveraging digital breast tomosynthesis (DBT) imaging data. Key objectives include: Developing a DBT-driven...